| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/19/2005 | CN1185219C Trans olefinic glucokinase activators |
| 01/19/2005 | CN1185217C Propanolamine derivatives, processes for their preparation, pharmaceuticals comprising these compounds, and their use |
| 01/19/2005 | CN1185215C Substituted glutarimides and use as IL-12 production inhibitors thereof |
| 01/19/2005 | CN1185214C Novel indeno indolone compound, its preparation method and drug composition comprising the same |
| 01/19/2005 | CN1185213C Azetidine derivatives, preparation and pharmaceutical compositions thereof |
| 01/19/2005 | CN1185007C Fat reducing and thrombosis dissolving medicine |
| 01/19/2005 | CN1185004C Blood sugar and fat reducing medicinal capsule |
| 01/19/2005 | CN1184989C Weight-reducing Chinese medicine acted on acupoint |
| 01/19/2005 | CN1184979C Medicine for treating diabetes and phthisis |
| 01/19/2005 | CN1184978C Traditional Chinese medicine for treating diabetes and keto acid toxication |
| 01/19/2005 | CN1184977C Yin nourishing and kidney reinforcing medicine |
| 01/19/2005 | CN1184959C Compositions containing ascorbic acid and pectin |
| 01/19/2005 | CN1184903C Method for stabilizing liquid nutritional products and products so stabilized |
| 01/18/2005 | US6844457 Antiproliferative agents; anticancer agents; antiinflammatory agents |
| 01/18/2005 | US6844449 Modifications of the trometamol salt of R-thioctic acid as well as a process for their production |
| 01/18/2005 | US6844445 Central nervous system disorders; psychological disorders |
| 01/18/2005 | US6844437 Chemical intermediates; anticholesterol agents, antilipemic agents |
| 01/18/2005 | US6844435 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 01/18/2005 | US6844372 Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same |
| 01/18/2005 | US6844347 Substituted 4-amino-2aryl-pyrimidines, their production and use and pharmaceutical preparations containing same |
| 01/18/2005 | US6844345 Piperazine derivatives |
| 01/18/2005 | US6844336 4-fluoroalkyl-2h-benzopyrans with anti-estogenic activity |
| 01/18/2005 | US6844335 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors |
| 01/18/2005 | US6844332 (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| 01/18/2005 | US6844331 (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| 01/18/2005 | US6844330 (20S)-1α-hydroxy-2α-methyl and 2β-methyl-19-NOR-vitamin D3 and their uses |
| 01/18/2005 | US6844329 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin |
| 01/18/2005 | US6844327 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/18/2005 | US6844314 Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
| 01/18/2005 | US6844180 Nucleotide sequences for use in the treatment of viral diseases, hypertension and coagulation defects |
| 01/18/2005 | US6844021 Oil or fat composition |
| 01/18/2005 | US6844011 Methods for inhibiting rejection of transplanted tissue |
| 01/18/2005 | US6844008 Tablet composition |
| 01/18/2005 | CA2149324C Fluidized intestinal submucosa and its use as an injectable tissue graft |
| 01/13/2005 | WO2005003146A1 The c-glycosylisoflavones having alkylaminoalkoxyl substituent, the preparation and the use of the same |
| 01/13/2005 | WO2005003135A1 Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| 01/13/2005 | WO2005003130A1 Novel pyrrolodihydroisoquinolines useful in the treatment of cancer |
| 01/13/2005 | WO2005003129A1 Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 01/13/2005 | WO2005003128A1 Thiazolylpiperidine derivatives as mtp inhibitors |
| 01/13/2005 | WO2005003119A1 2,4-bis(trifluoroethoxy)pyridine compound and medicine containing the same |
| 01/13/2005 | WO2005002612A1 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |
| 01/13/2005 | WO2005002606A1 Use of a single-cell protein material |
| 01/13/2005 | WO2005002605A1 Fish protein hydrolyzate |
| 01/13/2005 | WO2005002602A2 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |
| 01/13/2005 | WO2005002600A2 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus |
| 01/13/2005 | WO2004099192A3 Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
| 01/13/2005 | WO2004092130A3 N-containing heteroaromatic compounds as modulators of ppars and methods of treating metabolic disorders |
| 01/13/2005 | WO2004087880A8 Compounds and their use to treat diabetes and related disorders |
| 01/13/2005 | WO2004072047A8 Indoles, benzimidazoles or naphhimidazoles as histone deacetylase (hdac) inhibitors |
| 01/13/2005 | WO2004064764A3 Substituted alkyl amido piperidines |
| 01/13/2005 | WO2004042077A3 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b) |
| 01/13/2005 | WO2003084922A8 Acyl-4-carboxyphenylurea derivatives, method for production and use thereof |
| 01/13/2005 | WO2003072715A8 Gasp1: a follistatin domain containing protein |
| 01/13/2005 | US20050010284 Method for decreasing bioprosthetic implant failure |
| 01/13/2005 | US20050010052 P2X7 receptor (a ligand-gated ion channel) antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases; osteoarthritis |
| 01/13/2005 | US20050010047 Angiogenesis inhibitors; psoriasis; rheumatic disorders; chronic obstructive pulmonary disease |
| 01/13/2005 | US20050009897 Method of treatment |
| 01/13/2005 | US20050009894 Benzimidazole derivatives and their use as KDR kinase protein inhibitors |
| 01/13/2005 | US20050009893 Administering a renin-angiotensin system inhibitor, particularly an angiotensin-receptor-blocker, an ACE-inhibitor, or a vasopeptidase inhibitor, especially incombination with a hypotensive agent |
| 01/13/2005 | US20050009892 Phenyloxazole derivatives lower blood triglyceride, glucose, insulin; hyperlipidemia, arteriosclerosis, diabetes mellitus, hypertension, obesity; 2-methyl-2-[6-(5-methyl-2-phenyloxazol-4-yl)-(E)-4-hexenyloxy]propionic acid |
| 01/13/2005 | US20050009879 N-substituted-2-oxodihydropyridine derivatives |
| 01/13/2005 | US20050009867 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 01/13/2005 | US20050009852 human orexin receptor antagonists; analgesics, antidiabetic agents; sleep apnea, insomnia |
| 01/13/2005 | US20050009820 Thiochromenones used to combat painful conditions and neurodegenerative diseases |
| 01/13/2005 | US20050009816 Potassium channel modulators |
| 01/13/2005 | US20050009815 4-Aminoquinoline compounds |
| 01/13/2005 | US20050009812 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists |
| 01/13/2005 | US20050009792 (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses |
| 01/13/2005 | US20050009787 Complex of phosphate and ubiquinone, ascorbic acid, retinol, tocotriennol in mixture with carrier |
| 01/13/2005 | US20050009785 Heterocyclic compounds |
| 01/13/2005 | US20050009755 (74)(3S)-3-amino-1-(1-benzyl-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-4-yl)-5-methyl-2-heptanone for example; cysteine protease inhibitors; treating bone resorption diseases such as osteoporosis |
| 01/13/2005 | US20050009147 Parathyroid hormone variants; site-directed mutagenesis; for treatment of bone disorders |
| 01/13/2005 | US20050009140 Elongase genes and uses thereof |
| 01/13/2005 | US20050009025 A soluble T cell receptor for use as diagnostic indicator of infection and autoimmune diseases |
| 01/13/2005 | US20050009021 Isolated nucleic acid comprising polynucleotide of given sequence; diagnostic kits; use in treatment of cancer |
| 01/13/2005 | US20050008726 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 01/13/2005 | US20050008725 Synergistic mixture; adjust fat metabolism |
| 01/13/2005 | US20050008724 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 01/13/2005 | US20050008723 Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 01/13/2005 | US20050008722 Compositions incorporating(-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors |
| 01/13/2005 | US20050008712 Obesity therapy |
| 01/13/2005 | US20050008692 Compositions comprising pectin and ascorbic acid |
| 01/13/2005 | US20050008688 Oral administering; tablet with enteric coating; supplying drug to gastrointestinal systems |
| 01/13/2005 | US20050008655 Useful as barrier applied to skin; chemical and radiation resistance; skin disorders; autoimmune diseases; antitumor agents; topical applying |
| 01/13/2005 | US20050008630 Preservation; nutrients; foods; using ascorbic and citric acid; oxidation resistance; by-product inhibition |
| 01/13/2005 | CA2542401A1 Use of a single-cell protein material |
| 01/13/2005 | CA2542396A1 Fish protein hydrolyzate |
| 01/13/2005 | CA2531081A1 Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance |
| 01/13/2005 | CA2530317A1 Pyrrolodihydroisoquinolines useful in the treatment of cancer |
| 01/13/2005 | CA2530316A1 Pyrrolodihydroisoquinolines as pde10 inhibitors |
| 01/12/2005 | EP1496054A1 Medicinal composition for improving angiotension-regulating function of blood vessel endothelium |
| 01/12/2005 | EP1496052A1 Novel aminobenzamide derivative |
| 01/12/2005 | EP1495756A1 Severe sepsis preventive therapeutic agent |
| 01/12/2005 | EP1495053A2 Angiopoietin-2 specific binding agents |
| 01/12/2005 | EP1495034A2 Mimics of acyl coenzyme-a comprising pantolactone and pantothenic acid derivatives, compositions thereof, and methods of cholesterol management and related uses |
| 01/12/2005 | EP1495031A1 Labeled oxazinocarbazoles as diagnostic agents |
| 01/12/2005 | EP1495023A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same |
| 01/12/2005 | EP1495019A1 Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
| 01/12/2005 | EP1495004A2 Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor ligands |
| 01/12/2005 | EP1494997A1 Substituted aryl amides |